Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
University of Southern California
Jonsson Comprehensive Cancer Center
Universidad Nacional Autonoma de Mexico